Atlas Trials

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Clinical trial NCT03212521 · COMPLETED

Trial details

NCT number
NCT03212521
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis C Virus (HCV)
Start date
2017-08-07
Primary completion
2018-08-13
Enrollment
230

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.